Clinical Trial Update: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating nab-paclitaxel and bevacizumab followed by bevacizumab and erlotinib in metastatic breast cancer; completed with results posted in 2018…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: University of Washington | Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-12-04